Is Novartis (NVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear from the end of patent protection on some drugs.
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis: It's Not Too Late To Buy This Dividend Stock Now
Since my previous article in May, shares of Novartis AG have gone on to outperform the S&P 500 index. The drugmaker's revenue and core EPS topped analysts' expectations in Q3. Novartis' debt load remains very manageable.
Focus remains on R&D to drive growth of blockbuster drugs, says Novartis CEO
Vas Narasimhan, CEO at Novartis, discusses third-quarter results, and explains the strategy behind development of the company's most in-demand treatments.
Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns
Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth but investor disappointment stemmed from a revenue adjustment affecting Pluvicto. Novartis raised its full-year guidance, projecting double-digit sales growth for the remainder of 2024.
Novartis AG (NVS) Q3 2024 Earnings Call Transcript
Novartis AG (NYSE:NVS ) Q3 2024 Earnings Conference Call October 29, 2024 9:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Richard Vosser - J.P. Morgan Emily Field - Barclays Capital Florent Cespedes - Bernstein Simon Baker - Redburn Atlantic Graham Parry - Bank of America Matthew Weston - UBS James Quigley - Goldman Sachs Peter Welford - Jefferies Etzer Darout - BMO Capital Markets Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Securities Rajesh Kumar - HSBC Steve Scala - TD Cowen Emmanuel Papadakis - Deutsche Bank Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 Results Release Conference Call and Live Webcast.
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook
NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.
Novartis CEO on the impact of the U.S. election for pharma
Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on the business.
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Novartis Posts Results Above Estimates, Raises Outlook
Novartis (NVS) on Tuesday posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali.
